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Introduction: It is acknowledged that any claim of efficacy of allergen immunotherapy must be
done for each specific product, and this remains true also for venom immunotherapy (VIT). Thus,
we evaluated the efficacy and safety of a specific tyrosine-adsorbed VIT for vespula spp. and
honeybee in real-life.
Methods: Consecutive patients diagnosed with hymenoptera allergy, and receiving VIT for either
vespula or honeybee with a tyrosine-adsorbed preparation were observed to evaluate the grade
of reaction (according to Muller) at the first field re-sting. A modified ultra-rush protocol was used.
Results: A total of 247 patients (73 female) were observed (102 honeybee, group H, 145 vespula,
group V). Seventy-five patients in group H had a re-sting, and 74/75 had a lower grade reaction at
re-sting as compared to the pre-VIT reaction. Considering systemic reactions, protection was
achieved in 89% of patients. In group V 118 patients were re-stung, and 76/118 patients with
previous grade III-IV reaction had no more systemic reaction under VIT. Overall, considering
systemic reactions, protection was achieved in 92% of subjects. Of note, in both groups there was
a clear inverse correlation between the severity of pre-VIT and during VIT reactions.The duration of
VIT at the time of re-sting did not affect the efficacy. The safety was overall good, with 18% ad
15.4% local reactions in groups H and V, respectively.
Discussion: Modified extracts, including tyrosine-absorbed, have the aim of improving the safety
of VIT still yet maintaining the efficacy. Field re-sting is the best way to assess the efficacy in real
life. In this observational study we could confirm the protective efficacy of the tyrosine-adsorbed
extract, with a good safety expecially in the build-up using a modified-rush protocol.
Conclusion: The tyrosine-adsorbed VIT used herein is a viable and advantageous form of
treatment for hymenoptera allergy.
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Hymenoptera stings can provoke a wide range
of reactions in patients with hymenoptera venom
allergy (HVA),1,2 ranging from large local reactions
to systemic anaphylaxis and death. In particular, in
large local reactions the wheal-flare is larger than
10 cm and can persist for days, whereas systemic
reactions (SRs) may be generalized urticaria (with/
without angioedema), overt asthma, and hypo-
tension. Patients with a previous large local reac-
tion have a probability up to 25% of developing a
SR at subsequent stings, whereas in those with a
previous SR there is a risk of about 50% of having
another reaction of the same or higher degree of
severity.1,3,4
Hymenoptera venom immunotherapy (VIT) is
the only effective treatment able to prevent the
onset (or to reduce the degree of severity) of SRs at
re-sting in subjects with HVA, and shows a very
favorable safety profile.5 VIT is effective in more
than 95% of patients with wasp allergy and is
only slightly inferior for honeybee.6 Venom
extracts are commercialized either as aqueous or
“retard” (adsorbed to alum hydroxide or other
substances) preparations. The clinical efficacy is
similar with the 2 kinds of extracts. The aqueous
formulation allows a prompt availability of the
allergen, but this may increase the number and












Table 1. Build up phase of the modified-rush protocolTo avoid this inconvenience, a tyrosine-absorbed
extract has been introduced (Anallergo S.pA.,
Florence Italy). The advantage is, in fact, the
improved local tolerability, still yet maintaining the
clinical efficacy, that for the tyrosine-VIT (t-VIT) was
demonstrated in vivo for Polistes dominula and
Vespa crabro.7,8
The aim of this study was to prospectively eval-
uate in real-life the efficacy and safety of t-VIT with
honeybee and Vespula spp venoms in subjects
receiving the treatment, according to guidelines,
after a hymenoptera-induced SR.METHODS
A total of 247 consecutive patients with SRs to
Vespula spp (Group V) and to honeybee (Group H)
were enrolled between January 1995 and January
2018 at various allergy units in Italy. VIT was pre-
scribed according to current guidelines.9 The
diagnosis involved, as recommended: skin prick
test, intradermal test, and specific IgE assay (CAP
system, Thermofisher Scientific, Upssala, Sweden)
for honeybee, Vespula spp., Polistes dominula
and Vespa crabro. SRs were graded according to
Mueller's classification.10
VIT was given to all patients according to a
modified rush protocol.11 An aqueous extract (100












Volume 12, No. 12, Month 2019 33 sessions), then a tyrosine absorbed extract was
given (100 mcg/mL) in the maintenance period.
The interval between injections administered on
the same day was 30 minutes, and the patient
stayed for 1 hour under observation after the last
daily dose. The protocol is summarized in Table 1
The maintenance phase consisted of 1 injection
per month during the first year, and thereafter
every 6–8 weeks. The clinical efficacy was
evaluated recording the severity of reaction(s)
that occurred at field re-stings, and comparing
them to the severity at baseline (before VIT pre-
scription). Only those re-stings where the insect
was clearly identified by the patient were consid-
ered. The first field-resting was considered, unless
subsequent re-stings evidenced a higher grade of
severity. The safety was evaluated at each injection,
both in the build-up and maintenance periods.
Frequencies were tested by Pearson's chi-
square or binomial test, whereas means were
compared by Student t test o ANOVA for paired or
independent data, using the Tuckey's correction
for multiple comparisons.12 Moreover, the Sidak
correction was applied, when appropriate.13
Statistical significance estimates were performed,
for non-parametric tests, using the exact permu-
tation (pExact) or the Monte Carlo method (pMonte-
Carlo).
14 Analyses were made using IBM SPSS
Statistics ver. 25 (IBM, Chicago, IL, USA).
The local Ethical Committees were simply noti-
fied about the data collection, and no specific
approval was needed. All the still on VIT patients
signed an informed consent for the sensible dataG






Field re-sting during VIT, N(%)
Mean duration of VIT, years (range)
Table 2. Demographic and clinical dataprotection and privacy. All the diagnostic and
therapeutic procedures were part of the standard
of care, with a commercialized product.RESULTS
Group H involved 102 patients, 23 females and
79 males with a mean age of 49.1  1.6 years.
Males were more represented (Binomial test,
p < 0.001), with no difference in age between
genders. Their baseline (before VIT) reactions had
been grade I in 9.8% patients, grade II in 14.7%
grade III in 31.3% and grade IV in 44.1% of pa-
tients. No significant difference according to
grades of severity between men and women was
detected (Mann Whitney test, U ¼ 857.5,
W ¼ 4017.5, z ¼ 0.436, pExact>0.050), as well as
no association was seen between age and severity
of reactions (ANOVA, F3,98 ¼ 1.354, p > 0.05).
Group V included 145 subjects, 50 females and
95 males, with a mean age of 57.7  1.2 years,
again with a prevalence of male subjects (Binomial
test, z ¼ 3.654, p < 0.001). The grade of reaction
before VIT was grade I in 7,5% patients, grade II in
15,1%, grade III in 22,7% and grade IV in 54,4%
patients, again with no difference between men
and women, and no correlation with age. The de-
mographic and clinical data are summarized in
Table 2.
Seventy-five patients in group H and 118 in
group V had at least one re-sting during their VIT
course. In the total of the recorded reactions, the
stinging insect was clearly identified by patientsroup H N ¼ 102 Group V N ¼ 145
9/23 (77.4/22.6) 95/50 (65.5/34.5)
49 (16–78) 58 (22–85)
10 (9.8) 11 (7.6)
15 (14.7) 22 (15.2)
32 (31.3) 33 (22.7)
45 (44.2) 79 (54.5)
75 (74) 118 (81)
7(1–22) 8 (1–23)
4 Severino et al. World Allergy Organization Journal (2019) 12:100086
http://doi.org/10.1016/j.waojou.2019.100086(sometimes also by an entomologist). In group H,
in 74/75 re-stung patients, the reaction at re-sting
was of a lower grade compared to the pre-VIT
reaction (Wilcoxon paired test, z ¼ 7.547,
pExact<0.001). Only 1 patient had no change in the
severity of reaction (that remained of grade III).
(Fig. 1a). There was a strong inverse correlation
between the severity of reaction pre-VIT and that
at re-sting (rs ¼ 0.857, p < 0.001). In other words
effect was more apparent in those patients with the
more severe reactions pre-VIT. Since only 8/75
patients had a systemic reaction at re sting, the
overall protection was 89%. In Group V 118/145
were field re-stung. Also in this case there was an
overall significant decrease in the severity of re-
actions versus the pre-VIT situation: 76/118 pa-
tients with previous grade III or IV reaction had no
more systemic reactions during VIT (Wilcoxon
paired test, z ¼ 9.462, pExact<0.001). Only 3 pa-
tients were not protected, one maintaining a grade
IV reaction, one reducing from IV to III, and one
increasing from I to II. All the patients with pre-VIT
grade III reactions had none or only local reactions
during VIT (Fig. 1b). Globally, 9 patients still had
SRs (6 grade I) during VIT, thus we can assume
that t-VIT was protective in 92% of patients. Also
for Vespula VIT, there was a clear inverse
correlation between the severity of pre-VIT and


















GRADE ILARGE LOCALNO REACTIONI
A
Fig. 1 Number of patients with reactions by severity at re-sting (y axis)
Honeybee Group; B: Vespula groupConcerning safety, the tolerability was overall
satisfactory, considering that a modified rush pro-
tocol was applied. In group H local reactions
accounted for 18% patients during the build-up
and 3% during the manteinance phase (with
overall 6 LLR, 10 grade 1 and grade 2). Females
appeared more prone to experience adverse re-
actions during build-up, mainly with LLR and grade
I reactions (X23 ¼ 8.377, pExact ¼ 0.044), but this
difference disappeared in the maiteinance phase.
In group V local reactions were noticed in 15.4%
patients during build-up and in 2% patients during
mainteinance.
Of note, all those patients who experienced
mild adverse reactions during the build-up phase
could reach the 100 mcg maintenance dose. Also,
there was no significant correlation between the
duration of VIT and the re-sting reaction grade.DISCUSSION
VIT is overall effective in protecting at further
stings those subjects with HVA, as confirmed by
numerous trials ,5,9,15–17 where different extract
preparations were employed. The occurrence of
local (even systemic) reactions still represents one
of the main concerns, expecially with Honeybee-
VIT. In this regard, the use of adsorbed (depot or


















GRADE II GRADE III GRADE IV
B
according to the reaction experienced before VIT (x axis). A:
Volume 12, No. 12, Month 2019 5occurrence of reactions, when compared to
aqueous extracts. Several attempts to improve the
safety and tolerability of VIT were made, mainly
using the adsorption approach. There are reports
on the use of alum-adsorbed extracts and Rueff
et al.17 showed that alum-dsorbed formulations of
VIT achieved a reduction in the severity and fre-
quency of reactions at the site of injection. Quercia
et al.18 reported that alum-adsorbed VIT was bet-
ter tolerated during a rush induction protocol, and
this was confirmed by Alessandrini et al.19 with
Vespula VIT absorbed with alum salt.
The tyrosine absorption of VIT was already
described vith various VIT protocols,7,8 showing
that this formulation is effective, safe and
modulable. The present study, conducted as
observational, in patients with HVA and treated
with a t-VIT, showed that this formulation is
effective for both Vespula spp and honeybee
allergy, with a protection rate overall around 90%
of patients and with a slightly better efficacy and
tolerability for Vespula venom. The strenghtness
of the study resides that no surrogate biomarker
of efficacy was used, but the field re-sting with
the culprit insect, and that the VIT course was
prolonged enough, to assess the real-life effects.
Moreover, as an additional observation, the
extension to 3–4 months of the interval between
maintenance doses allowed to maintain the pro-
tection, as already previously suggested.20
Similarly, no relationship between the duration of
VIT and the time to the first re-sting was
observed and the modified rush protocol was well
tolerated.21
Since there is currently the need for the
demonstration of the efficacy of each single VIT
product, to avoid an unjustified claim for a generic
“class-effect”,22 we attempted to clinically confirm
the clinical efficacy and safety of a specific t-VIT
product, evaluating only very selected patients,
and using the field re-sting assessment criteria.
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